| Literature DB >> 33511638 |
Elnaz Khani1, Sajad Khiali1, Taher Entezari-Maleki1,2.
Abstract
Since the early days of 2020, the severe acute respiratory syndrome coronavirus 2 pandemic has become a global health concern. Currently, some therapies and vaccines have received US Food and Drug Administration approval or emergency use authorization for the management of coronavirus disease 2019. According to the pathophysiology of the disease, several medications have been evaluated in different clinical conditions of the disease. Evidence-based reviewing and categorizing these medications can guide the clinicians to select the proper medications according to each patient's condition. Therefore, we performed this review to categorize the coronavirus disease 2019 potential therapeutics and vaccines.Entities:
Keywords: COVID-19; IFN-β-1a; SARS-CoV-2; baricitinib; colchicine; convalescent plasma; dexamethasone; methylprednisolone; remdesivir; tocilizumab
Mesh:
Substances:
Year: 2021 PMID: 33511638 PMCID: PMC8014753 DOI: 10.1002/jcph.1822
Source DB: PubMed Journal: J Clin Pharmacol ISSN: 0091-2700 Impact factor: 3.126